Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg — CLARINET FORTE  

Midgut Neuroendocrine Tumours Clinical Trial

Official title: Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days

Status Completed

Clinical Trial Summary

This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Midgut Neuroendocrine Tumours
• Neoplasms
• Neuroendocrine Tumors
• Pancreatic Neoplasms
• Pancreatic Tumours

• NCT number: NCT02651987
• Study type: Interventional
• Source: Ipsen
• Status: Completed
• Phase: Phase 2
• Start date: December 15, 2015
• Completion date: October 24, 2019